Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evotec Se (EVO)

Evotec Se (EVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region

EVT : 25.20 (+1.47%)
EVO : 5.35 (+0.94%)
Evotec SE Provides Guidance Update

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its...

EVO : 5.35 (+0.94%)
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company...

RNXT : 1.2101 (+1.69%)
EVO : 5.35 (+0.94%)
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 339.64 (-0.70%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 3.29 (-0.90%)
AMC : 4.49 (+1.13%)
ONCT : 1.1600 (+1.75%)
EVO : 5.35 (+0.94%)
HLN : 9.55 (+0.74%)
CRBG : 31.47 (+2.71%)
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150,...

EVO : 5.35 (+0.94%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/CNW/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration...

EVO : 5.35 (+0.94%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic...

EVO : 5.35 (+0.94%)
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec’s Seattle-based subsidiary, Just –...

EVO : 5.35 (+0.94%)
ALPN : 64.97 (+0.02%)
Evotec SE Reports Results of Annual General Meeting 2022

HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the Company's...

EVO : 5.35 (+0.94%)
Evotec Enters a Drug Discovery Collaboration with Janssen

HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...

EVOTF : 9.4400 (+39.37%)
EVT : 25.20 (+1.47%)
EVO : 5.35 (+0.94%)

Barchart Exclusives

Up 882% YTD, Is It Too Late to Buy This Fintech Stock?
A recent guidance boost from DAVE propelled the stock even higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar